© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Dihydrostreptomycin sulfate has passed through clinics, farms, and labs for over half a century, showing the world both promise and limitation. Born out of the golden age of antibiotic discovery in the 1940s, scientists changed streptomycin using simple hydrogenation to form dihydrostreptomycin. At first, this tweak seemed simple, but it brought the expectation of greater potency and lower toxicity. Its story became a cautionary tale about how early optimism can fade once a drug lands in everyday practice. The excitement that greeted dihydrostreptomycin did not last once its drawbacks became clearer. Like its parent compound, it battles gram-negative bacteria and stubborn tuberculosis infections, but higher risks of ototoxicity held it back and limited its adoption. Regulatory agencies eventually cut human use, but veterinarians and food producers kept using it for infections in livestock and crop plants. A drug that once promised miracles mellowed into an ordinary tool, still useful, but with a reputation in need of repair.
A close look at this molecule in a chemistry lab reveals why it acts as it does. Dihydrostreptomycin sulfate appears as a nearly colorless, odorless crystalline solid. It dissolves well in water, thanks to the sulfate ion, making it easy to inject or mix—one reason why it found a purpose on farms and hospitals alike. The structure holds a complex lattice of carbon, hydrogen, oxygen, nitrogen, and sulfur, each interlocked in a way that resists most degradations but still gets handled by the kidney. Its chemical formula, C21H41N7O12•H2SO4, shows a molecule big enough to do real work against bacterial walls while small enough to fit into the gaps created by microbial protein synthesis machinery. This balance fits a pattern found in several older aminoglycoside antibiotics, which share both strengths and liabilities.
Dihydrostreptomycin sulfate does not come from nature as-is. Chemists in the post-war years wanted something better than original streptomycin. The synthetic step—catalytic hydrogenation—took out a double bond, turning streptomycin to dihydrostreptomycin. Simple in the hands of a trained chemist, this change created unexpected results after years of complicated clinical use. The new compound gained slightly more chemical stability and held up well under storage or shipping, but side effects stayed just as stubborn. The method for making this compound remains straightforward these days, relying on basic organic synthesis knowledge and workhorse reagents common to most pharmaceutical manufacturers.
This antibiotic does not offer much room for further tweaking. The difficulties in making chemical modifications without also raising toxicity dampened the efforts of researchers. Dihydrostreptomycin sulfate still undergoes the same sorts of basic reactions as other aminoglycosides—acid-base reactions, simple salt-forming exchanges—but with few viable offshoots for new drugs. Attempts to attach different functional groups, searching for more effective or safer derivatives, largely ended up in dead ends. Today, attention has shifted toward completely new antibiotic classes as resistance eats away at the old standbys.
Long after debuting, the drug wears many names: dihydrostreptomycin sulfate, dihydrostreptomycin monohydrate, and a litany of trade names from now-defunct brands or generic manufacturers. These synonyms once reflected a more global market with less regulation and rampant rebranding, but now they mostly serve historians and regulatory agencies trying to link product to active compound. It marks a time when naming confusion sometimes got in the way of safety monitoring.
Those who have had to handle dihydrostreptomycin sulfate know its utility comes with some heavy caveats. It brings a distinctive risk profile—chiefly, its ototoxic potential, causing damage to hearing or balance through its effects on cranial nerves. People working with the compound in veterinary or laboratory settings should never cut corners on protective equipment or disposal. Chronic exposure risks linger, affecting handlers and, in the agricultural setting, ecosystems as well. Regulations now restrict its use in many countries, especially in food animals, given the link between antibiotic residues, resistance, and public health. The experience of watching simple missteps—bad ventilation, ignored safety data sheets, skipped gloves—turn a manageable compound into a hazard brings home the need for institutional memory, training, and never trusting shortcuts.
Dihydrostreptomycin sulfate’s uses stick mostly to animal medicine and research. Vets sometimes rely on it for respiratory, urinary, and enteric infections in livestock, given its broad-spectrum punch and cost. Some countries still approve it for use against bacterial threats in crops. In research, this compound sometimes helps as a comparative or control agent in microbiology or pharmacology experiments. The field lost much of its faith in these drugs’ long-term utility for humans, but the legacy lingers. Livestock farmers who have faced outbreaks can attest that losing this tool, without a replacement, means watching herds suffer needlessly. Yet, each use must weigh real community health tradeoffs—spreading resistant microbes or having harmful residues show up in the food chain.
Research on dihydrostreptomycin sulfate keeps shrinking, especially in clinical medicine. Today’s scientists focus mostly on resistance in bacteria—how genes to defeat this molecule keep moving among species. Ongoing experiments use the compound to probe the details of protein synthesis in bacteria, looking for weak points in the ribosomal machinery that new antibiotics could hit. Despite fewer breakthroughs, these insights echo through the broader search for better infection defenses. Surveillance studies, cataloging resistant strains and mapping where the drug’s effectiveness disappears, remind us of the forgotten costs of overuse. Investigations into its environmental fate reveal soil microbes and water systems that carry antibiotic residues—problems that spread far wider than any one field or clinic.
Toxicity limits any dreams of widespread return to use. Ototoxicity and nephrotoxicity pull dihydrostreptomycin sulfate into the same trap as its older cousins. Real injuries have followed exposure, sometimes permanent. Studies keep pointing to the high price paid by those unlucky enough to need the drug’s intervention but unlucky in its side effects. Those using it in animals know the risks to muscles, nerves, and organs too. Long-term use in farms pointed to links between antibiotic-laced feed and the emergence of resistant bacteria that pass into people—a public health worry playing out globally. Even after all these years, gaps in understanding the drug’s subtle toxic effects linger, especially with frequent, low-dose exposures. Public and regulatory scrutiny keep pressure on to keep its use to a bare minimum.
Looking ahead, dihydrostreptomycin sulfate faces the real possibility of enforced retirement under broadening international regulations. Rising public pressure and policy built on lessons learned steer food and animal production to alternatives or to phase out antibiotic use for growth promotion. Synthetic biology, phage therapy, and newer antimicrobial classes offer at least a promise of escape from resistance deadlocks. As industry and health authorities seek better ways to safeguard antibiotics, old workhorses like dihydrostreptomycin sulfate serve mostly as reminders—not just of what early antibiotic chemistry achieved, but also what careless overuse can cost. For rural communities and developing economies, the drug may hold a narrower, time-limited place—until financial and technical hurdles toward modern replacements fall away. For now, its best lesson might be to put stewardship above convenience, hard as that can be for those facing pressure to cut costs or save livestock in crisis. The world has seen what happens when antibiotics get taken for granted. You don’t get a second chance if you let resistance win.
Dihydrostreptomycin sulfate lives in a world few people ever visit: animal medicine, especially veterinary antibiotics. Years ago, scientists looked for a way to curb infectious diseases in livestock and found that this compound, a close cousin of streptomycin, could take on some tough bacterial enemies. Its roots trace back to the larger family of aminoglycoside antibiotics, which target bacteria by blocking protein production. Many veterinarians have turned to dihydrostreptomycin sulfate to handle infections that threaten herds and flocks—usually in cattle, pigs, and sometimes in poultry.
People often don't realize the constant battle farmers face against diseases like brucellosis and tuberculosis in cattle. These infections make animals miserable, lower milk output, and sometimes jump to humans. Dihydrostreptomycin sulfate, often paired with penicillin, steps in to clear up infections that many other drugs can’t touch. Animals bounce back faster, farms suffer less loss, and families whose lives depend on these herds worry a bit less.
During visits to rural clinics, it’s common to see this compound stocked right alongside other lifesaving medicines. The real value shows up after disease sweeps through a barn. Fewer animals die. Less money gets lost. For veterinarians, seeing a once-limping calf up on its feet the next day feels like a victory, even if it isn’t big news in the city.
Modern farming relies on antibiotics. Yet every time one gets used, there’s a risk—that bacteria grow wise and develop resistance. Over the last decade, health experts around the world have sounded the alarm about this exact problem. Dihydrostreptomycin sulfate isn’t immune to these changes. Resistance creeps in, especially if these drugs get handed out too often or at the wrong doses. Some livestock industries pushed hard for tight rules on lots of antibiotics to slow this march. Dihydrostreptomycin sulfate fell under closer scrutiny, with officials recommending careful monitoring and strict guidelines.
The World Health Organization and national regulatory bodies have responded by limiting the use of certain antibiotics in food animals, encouraging alternatives and calling for only targeted, evidence-based treatment. Old habits can be slow to change, but many producers and vets have started routine lab testing before any prescription lands—a move that saves these drugs for cases where nothing else works.
A big part of the answer comes down to stewardship. Veterinarians and farmers need to work together, sharing information and tracking how antibiotics like dihydrostreptomycin sulfate are actually used. Having strict records forces everyone to think twice before reaching for the medicine cabinet. What’s more, research hasn’t stopped since this compound first arrived. Scientists keep looking for new approaches—vaccines, probiotics, and even smarter feeding and housing strategies that make animals less likely to get sick in the first place.
While antibiotics such as dihydrostreptomycin sulfate still fill a vital role, real change happens when prevention takes the lead. Clean water, good nutrition, and careful breeding can outmuscle many diseases before any bottle gets opened. In my own years meeting with food producers, the healthiest animals almost always come from farms that swear by these old-fashioned basics rather than depend on a backup antibiotic for every setback.
Dihydrostreptomycin sulfate treats certain bacterial infections and fights germs that can be tough to control. It doesn’t come without its set of problems. My experience listening to farmers and veterinarians talk about animal care has shown me how side effects shape both medicine choices and treatment plans, especially for livestock. While using strong antibiotics makes sense in some situations, being aware of side effects builds trust and helps everyone make better decisions.
Many people hear “antibiotic” and picture upset stomach or diarrhea, and they’re right: digestive problems happen pretty often. Nausea, vomiting, or loss of appetite can start during treatment. Some patients deal with stomach pain or loose stools. This antibiotic, given by injection, can feel rough at the site—a sore arm or leg, swelling, or a little redness. That’s a reminder it has real power, but doesn’t always go down easy. Hearing loss is a risk, too. Dihydrostreptomycin belongs to the aminoglycoside family, which means it can damage tiny hair cells in the ear. High doses or long use have caused permanent hearing loss in some patients. In animals, especially in horses, loss of hearing isn’t rare when dosed incorrectly. For people working in animal care or farming, accidental exposure or misuse brings similar risks.
The kidneys process and clear out dihydrostreptomycin, so they feel the brunt of high doses. Signs of kidney distress can start slow—maybe more thirst, less urine, or swelling in the feet and hands. Ignoring those signs stacks up trouble for the future. Some cases end with kidney failure, needing dialysis. People with weak kidneys face a higher risk from the start. Doctors monitor the patient’s blood throughout treatment, but not everyone gets that level of care. In rural animal care, for instance, careful dosing becomes as important as the choice of drug itself.Some users report numbness, tingling, or muscle weakness, which points to nerve problems. That kind of nerve damage mostly happens with long treatments or high amounts. It becomes harder for people to hold onto cups, type, or move around. I’ve watched older folks and kids need extra help recovering from even mild nerve issues after antibiotics.
Stopping every side effect isn’t possible. Using the lowest effective dose and regular check-ups help catch problems early. Veterinarians and doctors often suggest hearing tests and kidney checks if someone gets dihydrostreptomycin for more than one week. Anyone on this drug needs water and close observation for dehydration, headaches, or new weakness. For farmers and ranchers, safe handling protects everyone—gloves, proper storage, and clear dosing instructions keep medicine in the right hands. Teaching families and farm workers how to spot the early signs of hearing changes or urine problems equips them to speak up early.
Proper training, honest discussion, and fast action work best. In my community, conversations around side effects always guide better decision-making. Dihydrostreptomycin sulfate serves a real purpose in fighting stubborn infections, but a patient—or an animal—can only benefit if those giving and taking it understand both the help it brings and the help it sometimes takes away.
Dihydrostreptomycin sulfate stands out as one of those antibiotics that’s been around for generations of veterinary professionals. I have seen farm vets reach for it when animals show signs of serious bacterial infections. It’s clear—this drug isn’t a household name like penicillin, but it pulls weight where it counts, especially for livestock.
Most often, the substance gets into the animal’s system through injection. Vets and farmers work hard to make sure the medicine is given in just the right spot. Intramuscular administration is the usual route—right into the muscle, where the drug can spread into the bloodstream and start fighting bacteria. My own experience in the field taught me that picking the right muscle matters—neck, rump, or even thigh depending on the species and the animal’s size. It stings less if you go in smooth and steady, and if the animal’s calm, the process is over before they know it.
Dosing isn’t guesswork. Vets calculate it carefully based on the animal’s weight and the severity of the infection. Withholding periods, especially for milking cows or food animals, can’t be ignored. No one wants drug residues sneaking into milk or meat. It’s surprising to newcomers how these withdrawal times direct the whole treatment schedule. As someone who’s helped on dairy farms, letting a vet handle the calculations always struck me as the right call—farm income and public health both hang in the balance.
Dihydrostreptomycin sulfate treats serious infections, but using it without a plan can stir up trouble. Misuse can lead to resistance—a word that echoes through halls of veterinary clinics and even at kitchen tables when talking food safety. Overuse or sloppy dosing has consequences. Not long ago, I discussed with a cattleman how resistant bugs make future treatments tougher and riskier. Animals—and people—pay the price in the end.
Treating animals is part science, part experience. Vets inspect, diagnose, and then decide if this antibiotic fits the bill. They track the type of bacteria threatening the animal and check for drug sensitivity. Where money and livelihoods ride on healthy livestock, no one wants to gamble. I still remember one old ranch hand telling me: “You get one good shot at getting it right, so don’t rush the call.”
Access to professional guidance changes everything. Simple things—training, dosing guides, reminders on withdrawal times—help those giving the shots feel confident. I’ve noticed that keeping animal records cuts guesswork and mistakes. Clear handwriting and honest notes keep repeat errors off the farm. Checking needles and syringes for each use, and respecting clean techniques, make practical differences you can see and measure.
For folks in the business of animal care, sharing information about antimicrobial resistance can change habits. Honest conversation opens eyes. I have seen responsible vets sit with farmers and talk through every option—not just what’s fastest, but what’s safest for all. That kind of transparency wins trust and builds long-term respect for antibiotic power. It’s not just about getting the medicine into the animal, but thinking about every result that follows.
Anyone who’s dealt with veterinary antibiotics has probably run across dihydrostreptomycin sulfate. This drug, once widely used against bacterial infections in animals, especially cattle and swine, draws a lot of discussion due to its safety profile. Sometimes, it’s easy to overlook the downsides in favor of quick results, but those downsides matter.
Dihydrostreptomycin sits firmly in the aminoglycoside family. This type of antibiotic can damage nerves and hearing. Most people in animal healthcare know that already, but the full impact can sneak up. Hearing loss, or ototoxicity, often goes unnoticed in animals until it’s advanced. Kidney problems build slowly and can become a bigger battle than the original infection.
In the United States, the Food and Drug Administration cautioned against casual use of this medicine, especially after resistance patterns emerged. Even if it works well for a single round, repeat exposure steps up the chance for resistant bacteria and permanent animal harm.
Neonatal animals—those just a few days or weeks old—face the highest danger from dihydrostreptomycin. They tend to have underdeveloped organ systems, so the drug lingers in their bodies, often causing more damage. Pregnant animals aren’t safe either. Research shows this antibiotic passes through the placenta. A fetus has little defense against nerve-damaging drugs.
Animals already fighting kidney or liver issues get little benefit from taking dihydrostreptomycin. Those organs remove the antibiotic from the body. Struggling kidneys or a lagging liver can’t keep up, letting the drug build up and worsen the trouble.
Many farmers and veterinarians once saw dihydrostreptomycin as a lifeline for sick livestock. Back on the farm, a quick shot often meant less loss. Over time, repeated treatments sent more animals for culling due to deafness and kidney problems. Young calves sometimes didn’t make it at all.
Every regulated drug comes with withdrawal times for animals used in food production. Dihydrostreptomycin leaves residues in meat and milk, so producers must carefully keep track. Missing a withdrawal window could put tainted food into the market. No one wants to deal with recalls or sick consumers due to slip-ups.
Regular monitoring before and after giving dihydrostreptomycin lowers risks. Some clinics run kidney function tests to spot any trouble. Farmers started favoring alternative antibiotics with fewer side effects, as recommended by newer guidelines. Rotating between drug classes and teaming up with veterinary pharmacists cut down on resistance and toxic reactions.
Research keeps moving, pushing for safer and more efficient treatments. On-the-ground experience supports using a tailored approach. Choosing the right drug depends on animal age, health history, and the infection in question. Smart recordkeeping helps avoid repeat treatments and accidental overdosing.
Talking through options with a knowledgeable veterinarian prevents more harm than reading a drug label ever could. By slowing down and weighing the full risk, people can protect both their animals and the food supply.
Dihydrostreptomycin sulfate sounds like something that might belong on a high school chemistry test. For many, it’s just one more difficult-to-pronounce name. In reality, this antibiotic once played a huge role in treating various animal infections, especially in livestock. Today, it comes up less often because of resistance problems and health concerns, but plenty of people still want to know how much is safe — and how much actually works.
Most veterinary handbooks suggest a dose of 5–10 mg per kilogram of an animal’s body weight, delivered by deep intramuscular injection. Sometimes it’s grouped with another antibiotic, commonly procaine penicillin, and used for infections in cattle, pigs, or sheep. It’s not approved for human use these days, and any use in food animals draws strict attention from regulators because of residue and resistance worries.
My uncle ran a small cattle farm, and I remember watching the local veterinarian walk the line between underdosing and overdosing. Underdosing could mean the infection sticks around, spreads, or gets worse. Overdosing never improved the chances for a sick animal — it just increased side effects and the risk that leftover drugs would end up in the milk or meat. Following label instructions, body weight calculations, and respecting withdrawal periods were routine steps, not just paperwork for the bureaucrats, but real guardrails for public health.
Incorrect dosing opens a nasty can of worms. Too little dihydrostreptomycin encourages stronger, more resilient bacteria, resulting in resistant outbreaks — and those can jump from animal to human. Too much brings up kidney damage or hearing loss in animals, not to mention drug residues making their way into the food chain. Enforcement isn’t about being a stickler, it’s about protecting people and the environment. Blood levels drop off slowly after an injection, so withdrawal times (up to 30 days for meat from cattle treated this way) are set carefully for a reason.
Not all antibiotics belong in every barn. If you walk into a modern veterinary office, the team looks beyond historical recommendations. They’ll ask about the exact disease, the animal’s age, pregnancy status, and drug history. Laboratories can run sensitivity tests to confirm if the bacteria will respond before a prescription comes out. A veterinarian will rarely guess — they’ll measure, double-check, and document. Just using the highest or lowest estimate from a decades-old textbook may do more harm than good.
My years working on rural animal health projects taught me that knowledge gaps can push people into risky shortcuts. Training and regular updates for farmers and veterinarians make the critical difference. Push for tightly controlled prescriptions, weigh animals accurately, and don’t tempt fate by treating every sniffle or limp with antibiotics. Exploring better hygiene, alternative therapies, and effective vaccines cut down the need for drugs like dihydrostreptomycin in the first place.
Curiosity about proper dosing should always lead straight to a veterinarian or, in a human health emergency, a doctor. Professional experience and current research shape recommendations better than any guesswork on the internet. Dihydrostreptomycin isn’t just a substance: used unwisely, it becomes a real risk. Used caresully and by the book, it helps support both animal health and long-term food safety.
| Names | |
| Preferred IUPAC name | Dihydrostreptomycin sulfate |
| Other names |
Dihydrostreptomycin sulfate Dihydrostreptomycin hemisulfate Dihydrostreptomycin sulfate salt Dihydrostreptomycin sulfate (1:1) Dihydrostreptomycin sulphate |
| Pronunciation | /daɪˌhaɪdroʊˌstrɛp.təˈmaɪ.sɪn ˈsʌl.feɪt/ |
| Identifiers | |
| CAS Number | '5490-27-7' |
| 3D model (JSmol) | `3D model (JSmol)` string for **Dihydrostreptomycin Sulfate**: ``` data "Dihydrostreptomycin Sulfate" # 29759 # JSmol_model_string # 11040 # C21H41N7O12.1.5H2SO4 # CC1C(C(C(C(O1)N2C=NC(=NC2N)N)O)O)OC(C3C(C(C(C(O3)CO)O)O)N)C(=O)N # end ``` |
| Beilstein Reference | 1812200 |
| ChEBI | CHEBI:47383 |
| ChEMBL | CHEMBL21048 |
| ChemSpider | 20240193 |
| DrugBank | DB00484 |
| ECHA InfoCard | 03d9e2be-d9c8-41cc-91a6-780cc5d1015d |
| EC Number | 3.1.1.8 |
| Gmelin Reference | 10407 |
| KEGG | C01745 |
| MeSH | D006759 |
| PubChem CID | 441378 |
| RTECS number | QT1400000 |
| UNII | 9U1VM840SP |
| UN number | Dihydrostreptomycin Sulfate does not have a UN number |
| CompTox Dashboard (EPA) | DTXSID6023785 |
| Properties | |
| Chemical formula | C21H41N7O12·H2SO4 |
| Molar mass | 1457.42 g/mol |
| Appearance | White or almost white, hygroscopic powder |
| Odor | Odorless |
| Density | null |
| Solubility in water | Soluble in water |
| log P | -4.5 |
| Acidity (pKa) | 12.3 |
| Basicity (pKb) | 7.77 |
| Magnetic susceptibility (χ) | -7.8 × 10⁻⁶ cm³/mol |
| Viscosity | Viscous liquid |
| Dipole moment | 6.35 D |
| Pharmacology | |
| ATC code | J01GB01 |
| Hazards | |
| Main hazards | May cause allergic skin reaction; harmful if swallowed, inhaled, or absorbed through skin; may cause damage to organs through prolonged or repeated exposure. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS07, GHS08 |
| Signal word | Warning |
| Hazard statements | Hazard statements: "H302: Harmful if swallowed. H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | P261, P264, P272, P273, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338, P312, P330, P332+P313, P337+P313, P362+P364, P403+P233, P501 |
| Explosive limits | Non-explosive |
| Lethal dose or concentration | LD50 oral rat 5 g/kg |
| LD50 (median dose) | LD50 (oral, mouse): 5,000 mg/kg |
| NIOSH | RN: 54-91-1 |
| PEL (Permissible) | PEL: 0.1 mg/m³ |
| REL (Recommended) | 0.75 mg/kg |
| IDLH (Immediate danger) | Not listed |
| Related compounds | |
| Related compounds |
Streptomycin Streptidine Streptobiosamine |
